{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:58:01Z","timestamp":1789732681099,"version":"4.0.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.transci.2017.07.014","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T19:00:51Z","timestamp":1500145251000},"page":"612-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects"],"prefix":"10.1016","volume":"56","author":[{"given":"Jean","family":"Amiral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Peyrafitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dunois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Vissac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"February (2)","key":"10.1016\/j.transci.2017.07.014_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"January (1)","key":"10.1016\/j.transci.2017.07.014_bib0010","first-page":"45","article-title":"Pediatric antiphospholipid syndrome","volume":"10","author":"Berkun","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.transci.2017.07.014_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-015-0043-3","article-title":"Systemic lupus erythematosus and thrombosis","volume":"13","author":"Bazzan","year":"2015","journal-title":"Thrombosis J"},{"issue":"April (4)","key":"10.1016\/j.transci.2017.07.014_bib0020","first-page":"27","article-title":"Pediatric antiphospholipid syndrome","volume":"17","author":"Agular","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl. 1: M2","key":"10.1016\/j.transci.2017.07.014_bib0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1874303X01508010002","article-title":"The pathophysiology of antiphospholipid syndrome","volume":"8","author":"Sada","year":"2015","journal-title":"Open Urol Nephrol J"},{"key":"10.1016\/j.transci.2017.07.014_bib0030","first-page":"5","article-title":"Antiphospholipid antibody syndrome \u2013 diagnostic issues of lupus anticoagulants","volume":"4","author":"Tyagi","year":"2016","journal-title":"J Hematol Thromb Dis"},{"key":"10.1016\/j.transci.2017.07.014_bib0035","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br Med J"},{"issue":"August (2)","key":"10.1016\/j.transci.2017.07.014_bib0040","first-page":"228","article-title":"Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The N\u00eemes Obstetricians and Haematologists Study \u2013 NOHA","volume":"84","author":"Gris","year":"2000","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.transci.2017.07.014_bib0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.20452\/pamw.2025","article-title":"Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?","volume":"123","author":"Marchetti","year":"2013","journal-title":"Pol Arch Med Wewn"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2017.07.014_bib0050","first-page":"18","article-title":"Diagnosing antiphospholipid antibody syndrome: a review of the criterion for definite APS","volume":"8","author":"Dlott","year":"2015","journal-title":"Urol Nephrol J"},{"issue":"June (2)","key":"10.1016\/j.transci.2017.07.014_bib0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12288-015-0535-0","article-title":"A study of anti beta-2 glycoprotein I and anti-prothrombin antibodies in patients with unexplained recurrent pregnancy losses","volume":"32","author":"Singh","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"10.1016\/j.transci.2017.07.014_bib0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00001721-199807000-00005","article-title":"Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis","volume":"9","author":"Eschw\u00e8ge","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"August (2)","key":"10.1016\/j.transci.2017.07.014_bib0065","first-page":"538","article-title":"A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism","volume":"86","author":"Pasquier","year":"2001","journal-title":"Thromb Haemost"},{"issue":"March (3)","key":"10.1016\/j.transci.2017.07.014_bib0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-014-0494-8","article-title":"The significance and management of thrombocytopenia in antiphospholipid syndrome","volume":"17","author":"Artim-Esen","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.transci.2017.07.014_bib0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.5858\/2010-0325-RSR.1","article-title":"Antiphospholipid antibody syndrome","volume":"135","author":"Sangle","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"August (2)","key":"10.1016\/j.transci.2017.07.014_bib0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2796.2011.02362.x","article-title":"Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment","volume":"270","author":"Tripodi","year":"2011","journal-title":"J Intern Med"},{"issue":"May (Suppl. 1)","key":"10.1016\/j.transci.2017.07.014_bib0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ijlh.12507","article-title":"Laboratory testing for antiphospholipid syndrome","volume":"38","author":"Pengo","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"June (11)","key":"10.1016\/j.transci.2017.07.014_bib0090","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2017.07.014_bib0095","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood.V84.9.2854.2854","article-title":"Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other \u201cantiphospholipid\u201d autoantibodies","volume":"84","author":"Roubey","year":"1994","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.transci.2017.07.014_bib0100","first-page":"135","article-title":"Diagnostic approach of phospholipid-dependent antibodies","volume":"29","author":"Amiral","year":"1999","journal-title":"Haemostasis"},{"issue":"April (8)","key":"10.1016\/j.transci.2017.07.014_bib0105","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood.V87.8.3262.bloodjournal8783262","article-title":"Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system","volume":"87","author":"Igarashi","year":"1996","journal-title":"Blood"},{"issue":"September (3)","key":"10.1016\/j.transci.2017.07.014_bib0110","first-page":"393","article-title":"Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies","volume":"80","author":"Arvieux","year":"1998","journal-title":"Thromb Haemost"},{"issue":"January (5)","key":"10.1016\/j.transci.2017.07.014_bib0115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2007-12-129627","article-title":"How we diagnose the antiphospholipid syndrome","volume":"113","author":"Giannakopoulos","year":"2009","journal-title":"Blood"},{"issue":"February (4)","key":"10.1016\/j.transci.2017.07.014_bib0120","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2006-07-030148","article-title":"Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5","volume":"109","author":"de Laat","year":"2007","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.transci.2017.07.014_bib0125","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jth.12865","article-title":"Antiphospholipid syndrome: antibodies to Domain 1 of \u03b22-glycoprotein 1 correctly classify patients at risk","volume":"13","author":"Pengo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0130","doi-asserted-by":"crossref","first-page":"858542","DOI":"10.1155\/2015\/858542","article-title":"\u201cNew\u201d antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome","volume":"2015","author":"Misasi","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.transci.2017.07.014_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib5020012","article-title":"\u03b22GP1, anti-\u03b22GP1 antibodies and platelets: key players in the antiphospholipid syndrome","volume":"5","author":"Ho","year":"2016","journal-title":"Antibodies"},{"issue":"March (3)","key":"10.1016\/j.transci.2017.07.014_bib0140","first-page":"456","article-title":"Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men","volume":"75","author":"Vaarala","year":"1996","journal-title":"Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.transci.2017.07.014_bib0145","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/096120339800700208","article-title":"Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant","volume":"7","author":"de Groot","year":"1998","journal-title":"Lupus"},{"issue":"April (4)","key":"10.1016\/j.transci.2017.07.014_bib0150","first-page":"924","article-title":"Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases","volume":"27","author":"Lakos","year":"2000","journal-title":"J Rheumatol"},{"issue":"August (2)","key":"10.1016\/j.transci.2017.07.014_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.thromres.2010.05.018","article-title":"Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA)","volume":"126","author":"Pengo","year":"2010","journal-title":"Thromb Res"},{"issue":"March (3)","key":"10.1016\/j.transci.2017.07.014_bib0160","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.thromres.2013.12.001","article-title":"Validation of a commercially available kit to detect anti-phosphatidylserine\/prothrombin antibodies in a cohort of systemic lupus erythematosus patients","volume":"133","author":"Sciascia","year":"2014","journal-title":"Thromb Res"},{"issue":"September (2)","key":"10.1016\/j.transci.2017.07.014_bib0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13317-014-0061-3","article-title":"The introduction of anti-phosphatidylserine\/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation","volume":"5","author":"Fabris","year":"2014","journal-title":"Auto Immun Highlights"},{"issue":"May (2)","key":"10.1016\/j.transci.2017.07.014_bib0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/cei.12573","article-title":"Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine\/prothrombin antibodies in an at-risk patient cohort","volume":"180","author":"Heikal","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2017.07.014_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2015.10.003","article-title":"Antibodies to phosphatidylserine\/prothrombin complex in antiphospholipid syndrome: analytical and clinical perspectives","volume":"73","author":"Peterson","year":"2016","journal-title":"Adv Clin Chem"},{"issue":"September (3)","key":"10.1016\/j.transci.2017.07.014_bib0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-3476(95)70063-3","article-title":"Postinfectious purpura fulminans caused by an autoantibody directed against protein S","volume":"127","author":"Levin","year":"1995","journal-title":"J Pediatr"},{"issue":"January\u2013February (1)","key":"10.1016\/j.transci.2017.07.014_bib0185","first-page":"99","article-title":"Post-varicella cerebral thrombophlebitis with anti-protein S: report of a pediatric case","volume":"70","author":"Samyn","year":"2012","journal-title":"Ann Biol Clin (Paris)"},{"issue":"June (1\u20132)","key":"10.1016\/j.transci.2017.07.014_bib0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2011.03.017","article-title":"Clinical significance of anti-annexin V antibody in acute cerebral ischemia","volume":"305","author":"Lee","year":"2011","journal-title":"J Neurol Sci"},{"issue":"July (3)","key":"10.1016\/j.transci.2017.07.014_bib0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tmrv.2016.04.001","article-title":"Acquired Factor XIII inhibitor in hospitalized and perioperative patients: a systematic review of case reports and case series","volume":"30","author":"Tone","year":"2016","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2017.07.014_bib0200","first-page":"100","article-title":"Standardization of immunoassays for antiphospholipid antibodies with \u03b22GPI and role of other phospholipid cofactors","volume":"29","author":"Amiral","year":"1999","journal-title":"Haemostasis"},{"issue":"July","key":"10.1016\/j.transci.2017.07.014_bib0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12948-016-0043-2","article-title":"Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay","volume":"14","author":"Sciascia","year":"2016","journal-title":"Clin Mol Allergy"},{"issue":"3","key":"10.1016\/j.transci.2017.07.014_bib0210","first-page":"187","article-title":"Laboratory diagnosis of antiphospholipid syndrome","volume":"59","author":"Pengo","year":"2007","journal-title":"Reumatismo"},{"issue":"January (1)","key":"10.1016\/j.transci.2017.07.014_bib0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0961203312460722","article-title":"Diagnosis of antiphospholipid syndrome in routine clinical practice","volume":"22","author":"Gardiner","year":"2013","journal-title":"Lupus"},{"issue":"November (8361)","key":"10.1016\/j.transci.2017.07.014_bib0220","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"322","author":"Harris","year":"1983","journal-title":"Lancet"},{"issue":"June (12)","key":"10.1016\/j.transci.2017.07.014_bib0225","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1182\/blood-2002-12-3802","article-title":"Anti-protein Z antibodies in women with pathologic pregnancies","volume":"101","author":"Gris","year":"2003","journal-title":"Blood"},{"issue":"May (10)","key":"10.1016\/j.transci.2017.07.014_bib0230","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood.V81.10.2618.2618","article-title":"Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?","volume":"81","author":"Oosting","year":"1993","journal-title":"Blood"},{"issue":"October (1)","key":"10.1016\/j.transci.2017.07.014_bib0235","first-page":"110","article-title":"Monoclonal hybridoma anti-cardiolipin antibodies from SLE mice","volume":"74","author":"Ichikawa","year":"1988","journal-title":"Clin Exp Immunol"},{"issue":"May (9)","key":"10.1016\/j.transci.2017.07.014_bib0240","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1172\/JCI119401","article-title":"Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids","volume":"99","author":"Takeya","year":"1997","journal-title":"J Clin Invest"},{"issue":"November (11)","key":"10.1016\/j.transci.2017.07.014_bib0245","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/1529-0131(199911)42:11<2461::AID-ANR25>3.0.CO;2-O","article-title":"A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies","volume":"42","author":"Ichikawa","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transci.2017.07.014_bib0250","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1538-7836.2011.04448.x","article-title":"ISTH\/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?","volume":"9","author":"Jennings","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"April (1)","key":"10.1016\/j.transci.2017.07.014_bib0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"issue":"June (3)","key":"10.1016\/j.transci.2017.07.014_bib0260","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ijlh.12227","article-title":"Commonalities and contrasts in recent guidelines for lupus anticoagulant detection","volume":"36","author":"Moore","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.transci.2017.07.014_bib0265","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/jth.12537","article-title":"Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH","volume":"12","author":"Devreese","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.transci.2017.07.014_bib0275","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00270303","article-title":"Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE","volume":"5","author":"Asherson","year":"1985","journal-title":"Rheumatol Int"},{"issue":"July (753)","key":"10.1016\/j.transci.2017.07.014_bib0280","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/pgmj.64.753.517","article-title":"Systemic lupus erythematosus","volume":"64","author":"Hughes","year":"1988","journal-title":"Postgrad Med J"},{"issue":"December (12)","key":"10.1016\/j.transci.2017.07.014_bib0285","first-page":"1376","article-title":"The effect of phospholipid on the detection of lupus anticoagulants by the dilute Russell viper venom time","volume":"113","author":"Brandt","year":"1989","journal-title":"Arch Pathol Lab Med"},{"issue":"August (3)","key":"10.1016\/j.transci.2017.07.014_bib0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001721-199008000-00002","article-title":"Use of a simplified dilute Russell's viper venom time (DRVVT) confirms heterogeneity among \u2018lupus anticoagulants\u2019","volume":"1","author":"Exner","year":"1990","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"April (3)","key":"10.1016\/j.transci.2017.07.014_bib0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00001721-200404000-00015","article-title":"Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants","volume":"15","author":"Moore","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.transci.2017.07.014_bib0300","unstructured":"Braun A. Anticoagulation in antiphospholipid antibody syndrome. Pharmacotherapy Rounds (Oct 2005). Available from https:\/\/pdfs.semanticscholar.org\/6070\/78ef58293908efc4152e45edde360b6f735e.pdf."},{"issue":"February (1)","key":"10.1016\/j.transci.2017.07.014_bib0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3343\/kjlm.2010.30.1.38","article-title":"Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus","volume":"30","author":"Woo","year":"2010","journal-title":"Korean J Lab Med"},{"key":"10.1016\/j.transci.2017.07.014_bib0310","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0315","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","article-title":"Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time","volume":"9","author":"van Os","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0320","article-title":"Overview of Factor Xa inhibitors: evaluation, bleeding management, and what's coming next","author":"Annen","year":"2014","journal-title":"Blood Bulletin by America's Blood Centers"},{"issue":"July (7)","key":"10.1016\/j.transci.2017.07.014_bib0325","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/jth.12917","article-title":"Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome","volume":"13","author":"Arachchillage","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"May (5)","key":"10.1016\/j.transci.2017.07.014_bib0330","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.thromres.2015.01.028","article-title":"The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases","volume":"135","author":"Son","year":"2015","journal-title":"Thromb Res"},{"issue":"January","key":"10.1016\/j.transci.2017.07.014_bib0335","article-title":"Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?","author":"Resseguier","year":"2017","journal-title":"Lupus"},{"issue":"February (2)","key":"10.1016\/j.transci.2017.07.014_bib0340","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.autrev.2016.12.010","article-title":"Detection of lupus anticoagulant in the era of direct oral anticoagulants","volume":"16","author":"Hoxha","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"Issue #1, 2011","key":"10.1016\/j.transci.2017.07.014_bib0345","article-title":"Update on lupus anticoagulant and antiphospholipid antibody syndrome","author":"Chibisov","year":"2011","journal-title":"Coagulation update"},{"issue":"November (9)","key":"10.1016\/j.transci.2017.07.014_bib0350","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ad.2012.01.016","article-title":"Widespread cutaneous necrosis as the first clinical manifestation of secondary antiphospholipid syndrome","volume":"103","author":"Perell\u00f3-Alzamora","year":"2012","journal-title":"Actas Dermosifiliogr"},{"issue":"January","key":"10.1016\/j.transci.2017.07.014_bib0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-015-0521-9","article-title":"Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register","volume":"17","author":"Ighe","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.transci.2017.07.014_bib0360","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/jth.13020","article-title":"Mixing studies in lupus anticoagulant testing are required at least in some type of samples","volume":"13","author":"Devreese","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0365","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/antib5040022","article-title":"Current controversies in lupus anticoagulant detection","volume":"5","author":"Moore","year":"2016","journal-title":"Antibodies"},{"issue":"April (4)","key":"10.1016\/j.transci.2017.07.014_bib0370","first-page":"385","article-title":"Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids","volume":"95","author":"Kamboh","year":"1995","journal-title":"Hum Genet"},{"key":"10.1016\/j.transci.2017.07.014_bib0375","first-page":"191","article-title":"Standardization of immunoassays for antiphospholipid antibodies with \u03b22GPI and role of other phospholipid cofactors","volume":"24","author":"Amiral","year":"1994","journal-title":"Haemostasis"},{"issue":"July (2)","key":"10.1016\/j.transci.2017.07.014_bib0380","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V86.2.617.bloodjournal862617","article-title":"Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies","volume":"86","author":"Galli","year":"1995","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.transci.2017.07.014_bib0385","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1538-7836.2003.00146.x","article-title":"A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants","volume":"1","author":"Simmelink","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"March (6)","key":"10.1016\/j.transci.2017.07.014_bib0390","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V91.6.1999","article-title":"Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C","volume":"91","author":"Galli","year":"1998","journal-title":"Blood"},{"issue":"June (3)","key":"10.1016\/j.transci.2017.07.014_bib0395","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ijlh.12234","article-title":"Antiphospholipid antibody testing and standardization","volume":"36","author":"Devreese","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.transci.2017.07.014_bib0400","doi-asserted-by":"crossref","first-page":"983094","DOI":"10.1155\/2015\/983094","article-title":"Increased performances of the biological diagnosis of the antiphospholipid syndrome by the use of a multiplex assay","volume":"2015","author":"S\u00e9nant","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.transci.2017.07.014_bib0405","first-page":"2","article-title":"Reactivity against the five domains of \u03b2 glycoprotein I: a focus on systemic lupus erythematosus","volume":"5","author":"Chighizola","year":"2014","journal-title":"J Clin Cell Immunol"},{"issue":"April (1)","key":"10.1016\/j.transci.2017.07.014_bib0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(97)00047-9","article-title":"Association of lupus anticoagulant with transient antibodies to prothrombin in a patient with hypoprothrombinemia","volume":"86","author":"Amiral","year":"1997","journal-title":"Thromb Res"},{"issue":"August (2)","key":"10.1016\/j.transci.2017.07.014_bib0415","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.thromres.2009.11.025","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome (HLAS): report of one case in a familial infectious context","volume":"126","author":"Appert-Flory","year":"2010","journal-title":"Thromb Res"},{"issue":"September (3)","key":"10.1016\/j.transci.2017.07.014_bib0420","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0955-3886(97)00032-5","article-title":"Immunomodulation, autoimmunity and haemostatic dysfunctions","volume":"18","author":"Amiral","year":"1997","journal-title":"Transfus Sci"},{"issue":"August","key":"10.1016\/j.transci.2017.07.014_bib0425","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-065X.1998.tb01204.x","article-title":"Persisting viruses and chronic inflammation: understanding their relation to autoimmunity","volume":"164","author":"Di Rosa","year":"1998","journal-title":"Immunol Rev"},{"issue":"September (9)","key":"10.1016\/j.transci.2017.07.014_bib0430","first-page":"519","article-title":"Autoantibodies in autoimmune diseases: clinical and critical evaluation","volume":"18","author":"Kapsogeorgou","year":"2016","journal-title":"Isr Med Assoc J"},{"issue":"January (1)","key":"10.1016\/j.transci.2017.07.014_bib0435","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clim.2012.10.005","article-title":"The role of B lymphocytes in the progression from autoimmunity to autoimmune disease","volume":"146","author":"Salinas","year":"2013","journal-title":"Clin Immunol"},{"issue":"March (3)","key":"10.1016\/j.transci.2017.07.014_bib0440","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.1993.tb04672.x","article-title":"Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles","volume":"83","author":"Galli","year":"1993","journal-title":"Br J Haematol"},{"issue":"September (5)","key":"10.1016\/j.transci.2017.07.014_bib0445","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood.V92.5.1652","article-title":"Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a \u201clupus procoagulant\u201d phenomenon","volume":"92","author":"Rand","year":"1998","journal-title":"Blood"},{"issue":"October (3)","key":"10.1016\/j.transci.2017.07.014_bib0450","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bcmd.2015.06.011","article-title":"Factors contributing to APC-resistance in women with recurrent spontaneous miscarriages: Indian perspective","volume":"55","author":"Sharma","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"December (6)","key":"10.1016\/j.transci.2017.07.014_bib0455","first-page":"925","article-title":"The Textarin\/Ecarin ratio: a confirmatory test for lupus anticoagulants","volume":"70","author":"Triplett","year":"1993","journal-title":"Thromb Haemost"},{"issue":"May (1)","key":"10.1016\/j.transci.2017.07.014_bib0460","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2141.1994.tb04876.x","article-title":"Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin","volume":"87","author":"Arnout","year":"1994","journal-title":"Br J Haematol"},{"issue":"November (3)","key":"10.1016\/j.transci.2017.07.014_bib0465","first-page":"892","article-title":"Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids","volume":"62","author":"Rauch","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2017.07.014_bib0470","series-title":"Laboratory testing for the lupus anticoagulant. Approved guideline","author":"Ledford-Kraemer","year":"2014"},{"issue":"January (1)","key":"10.1016\/j.transci.2017.07.014_bib0475","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/cclm-2016-0245","article-title":"Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well-considered choice","volume":"55","author":"Depreter","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"April (2)","key":"10.1016\/j.transci.2017.07.014_bib0480","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijlh.12006","article-title":"Lupus anticoagulant detection: out of control?","volume":"35","author":"Moore","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.transci.2017.07.014_bib0485","doi-asserted-by":"crossref","DOI":"10.1177\/0961203317711773","article-title":"Newly developed dilute Russell\u2019s viper venom reagents for lupus anticoagulant detection with improved specificity","author":"Moore","year":"2017","journal-title":"Lupus"},{"issue":"March","key":"10.1016\/j.transci.2017.07.014_bib0490","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.thromres.2016.01.019","article-title":"Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulant","volume":"139","author":"Moore","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2017.07.014_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/641962","article-title":"Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease","volume":"2014","author":"Serrano","year":"2014","journal-title":"J Immunol Res"},{"issue":"December (2)","key":"10.1016\/j.transci.2017.07.014_bib0500","first-page":"1","article-title":"Relation of immunoglobulin A isotype of anti-\u03b22 glycoprotein I to clinical and laboratory features of antiphospholipid syndrome and systemic lupus erythematosus","volume":"82","author":"El-Awar","year":"2014","journal-title":"Med J Cairo Univ"},{"issue":"April (8)","key":"10.1016\/j.transci.2017.07.014_bib0505","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1016\/S0021-9258(18)32490-6","article-title":"Beta 2-glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H","volume":"258","author":"Lee","year":"1983","journal-title":"J Biol Chem"},{"issue":"May (1)","key":"10.1016\/j.transci.2017.07.014_bib0510","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0929-7855(96)00564-0","article-title":"Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography","volume":"16","author":"Gambino","year":"1997","journal-title":"J Lipid Mediat Cell Signal"},{"key":"10.1016\/j.transci.2017.07.014_bib0515","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1073\/pnas.81.12.3640","article-title":"Complete amino acid sequence of human plasma \u03b22-glycoprotein I","volume":"81","author":"Lozier","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2017.07.014_bib0520","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V66.5.1086.1086","article-title":"Beta 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway","volume":"66","author":"Schousboe","year":"1985","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2017.07.014_bib0525","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-5223(19)34162-5","article-title":"Immunization by bovine thrombin used with fibrin glue during cardiovascular operations: development of thrombin and factor V inhibitors","volume":"105","author":"Berruyer","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"September (6)","key":"10.1016\/j.transci.2017.07.014_bib0530","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/08916930500288356","article-title":"Antibodies against annexin A5: detection pitfalls and clinical associations","volume":"38","author":"Bozic","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.transci.2017.07.014_bib0535","series-title":"1st international reference panel for lupus anticoagulant. NIBSC code: 13\/172 Instructions for use (version 1.0, dated 23\/02\/2015)","author":"WHO Reference Panel","year":"2015"},{"issue":"May (9)","key":"10.1016\/j.transci.2017.07.014_bib0540","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1172\/JCI119401","article-title":"Anti-\u03b22-glycoprotein I (\u03b22GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the \u03b22GPI binding to phospholipids","volume":"99","author":"Takeya","year":"1997","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.transci.2017.07.014_bib0545","doi-asserted-by":"crossref","DOI":"10.23736\/S0031-0808.17.03324-9","article-title":"Catastrophic antiphospholipid syndrome: an update","volume":"59","author":"Espinosa","year":"2017","journal-title":"Panminerva Med"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:33:59Z","timestamp":1750635239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050217301428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1473050217301428"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2017.07.014","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2017.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}